STOCK TITAN
  1. Home
  2. Sec-filings
  3. WGS
  4. [Form 4] GeneDx Holdings Corp. Insider Trading Activity

[Form 4] GeneDx Holdings Corp. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fuchs Thomas reported acquisition or exercise transactions in this Form 4 filing.

GeneDx Holdings Corp. director Thomas Fuchs received an equity compensation award in the form of 4,248 restricted stock units on June 18, 2026. Each RSU represents a contingent right to receive one share of Class A common stock upon settlement for no cash payment.

The entire award will vest on the earlier of the company’s 2027 annual stockholder meeting or the first anniversary of the grant date, as long as Fuchs continues to serve the company through that date. If service ends before vesting, the units may be cancelled rather than vest. Following this grant, Fuchs is reported as holding 4,248 RSUs, and no open‑market purchases or sales are disclosed in this filing.

Positive

  • None.

Negative

  • None.
Insider Fuchs Thomas
Role null
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 4,248 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 4,248 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fuchs Thomas
(Last)(First)(Middle)
C/O GENEDX HOLDINGS CORP.
333 LUDLOW ST., NORTH TOWER, 6TH FLOOR
(Street)
STAMFORD CONNECTICUT 06902
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
GeneDx Holdings Corp. [ WGS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)06/18/2026A4,248 (2) (2)Class A Common Stock4,248$04,248D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
2. The entire award shall vest on the earlier of the (i) date of the 2027 annual meeting of the Issuer's stockholders, or (ii) first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. These RSUs do not have an expiration date; they either vest or are cancelled prior to the vesting date.
/s/ Bridget Brown, Attorney-in-Fact06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Thomas Fuchs report at GeneDx Holdings (WGS)?

Thomas Fuchs reported receiving 4,248 restricted stock units as an equity award. These RSUs are a form of compensation, not an open-market purchase or sale, and give him the right to receive Class A common shares if vesting conditions are met.

How many GeneDx (WGS) restricted stock units did Thomas Fuchs receive?

He received 4,248 restricted stock units linked to GeneDx Class A common stock. After this grant, his reported holdings of these RSUs total 4,248 units, reflecting the entire new award disclosed in this Form 4 filing.

When do Thomas Fuchs’ GeneDx (WGS) RSUs vest?

The RSUs vest on the earlier of the 2027 GeneDx annual stockholder meeting or the first anniversary of the June 18, 2026 grant date. Vesting requires Fuchs to continue serving the company through that vesting date.

Does Thomas Fuchs pay anything to receive GeneDx (WGS) shares from these RSUs?

No cash payment is required for settlement of these RSUs. Each restricted stock unit converts into one share of GeneDx Class A common stock for no consideration if the vesting conditions are satisfied and the award is not cancelled.

Do Thomas Fuchs’ GeneDx (WGS) RSUs have an expiration date?

The RSUs do not have a traditional expiration date. They either vest on the specified vesting date if service conditions are met or are cancelled before vesting, meaning the right to receive shares is forfeited.

Did Thomas Fuchs buy or sell GeneDx (WGS) shares in the market in this Form 4?

No market trades were reported. The Form 4 only shows a grant of 4,248 restricted stock units as compensation. There are no open-market purchases or sales of GeneDx Class A common stock disclosed in this filing.